Systemic therapy for sarcomatoid renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 11, Issue 6, 2011, Pages 913-920

  Pagliaro, Lance C ^a   Tannir, Nizar ^a   Sircar, Kanishka ^a   Jonasch, Eric ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

bevacizumab; chemotherapy; drug therapy; immunotherapy; kidney neoplasm; sarcomatoid neoplasm

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DOXORUBICIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANTIANGIOGENIC THERAPY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CLEAR CELL CARCINOMA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; NEPHRECTOMY; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SARCOMATOID KIDNEY CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS;

EID: 79959801387     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.39     Document Type: Review

References (55)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010
2. Yagoda A. Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin. Oncol. 22, 42-60 (1995
3. Motzer RJ. Renal cell carcinoma: a priority malignancy for development and study of novel therapies. J. Clin. Oncol. 21, 1193-1194 (2003
4. Farrow GM, Harrison EG Jr, Utz DC, ReMine WH. Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults. Cancer 22, 545-550 (1968
5. Ro JY, Ayala AG, Sella A, Samuels ML, Swanson DA. Sarcomatoid renal cell carcinoma: clinicopathologic. A study of 42 cases. Cancer 59, 516-526 (1987 (Pubitemid 17002432)
6. Kuroda N, Toi M, Hiroi M et al. Review of sarcomatoid renal cell carcinoma with focus on clinical and pathobiological aspects. Histol. Histopathol. 18, 551-555 (2003 (Pubitemid 36362073)
7. Akhtar M, Tulbah A, Kardar AH, Ali MA. Sarcomatoid renal cell carcinoma: the chromophobe connection. Am. J. Surg. Pathol. 21, 1188-1195 (1997
8. Tong GX, Yu WM, Beaubier NT et al. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod. Pathol. 22, 1218-1227 (2009
9. de Peralta-Venturina M, Moch H, Amin M et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am. J. Surg. Pathol. 25, 275-284 (2001 (Pubitemid 32174196)
10. Shuch B, Said J, LaRochelle JC et al. Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer 116, 616-624 (2010
11. Gokden N, Nappi O, Swanson PE et al. Renal cell carcinoma with rhabdoid features. Am. J. Surg. Pathol. 24, 1329-1338 (2000
12. Kuroiwa K, Kinoshita Y, Shiratsuchi H et al. Renal cell carcinoma with rhabdoid features: an aggressive neoplasm. Histopathology 41, 538-548 (2002 (Pubitemid 36693600)
13. Leroy X, Zini L, Buob D et al. Renal cell carcinoma with rhabdoid features: an aggressive neoplasm with overexpression of p53. Arch. Pathol. Lab. Med. 131, 102-106 (2007 (Pubitemid 46174143)
14. Storkel S, Eble JN, Adlakha K et al. Classification of renal cell carcinoma: workgroup no. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCCCancer 80, 987-989 (1997
15. Dal Cin P, Sciot R, Van Poppel H et al. Chromosome changes in sarcomatoid renal carcinomas are different from those in renal cell carcinomas. Cancer Genet. Cytogenet. 134, 38-40 (2002 (Pubitemid 34462107)
16. Jiang F, Moch H, Richter J et al. Comparative genomic hybridization reveals frequent chromosome 13q and 4q losses in renal carcinomas with sarcomatoid transformation. J. Pathol. 185, 382-388 (1998 (Pubitemid 28355970)
17. Mian BM, Bhadkamkar N, Slaton JW et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J. Urol. 167, 65-70 (2002 (Pubitemid 34024501)
18. Amin MB Tamboli P, Javidan J et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am. J. Surg. Pathol. 26, 281-291 (2002). (Pubitemid 34184451)
19. Kassouf W, Sanchez-Ortiz R, Tamboli P et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J. Urol. 178, 1896-1900 (2007 (Pubitemid 47538613)
20. Abel EJ, Culp SH, Matin SF et al. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J. Urol. 184, 1877-1881 (2010
21. Shuch B, Said J, La Rochelle JC et al. Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology - is up-front resection indicated and, if not, is it avoidable? J. Urol. 182, 2164-2171 (2009
22. Kutikov A, Uzzo RG, Caraway A et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int. 106, 218-223 (2009
23. Escudier B, Bellmunt J, Negrier S et al. Phase III trial of bevacizumab plus interferon a-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 28, 2144-2150 (2010
24. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003 (Pubitemid 36910021)
25. Jonasch E, Lal L, Atkinson B et al. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine, and bevacizumab at a tertiary cancer center. BJU Int. 107(5), 741-747 (2011
26. Chung EK, Posadas EM, Kasza K et al. A Phase II trial of gemcitabine capecitabine, and bevacizumab in metastatic renal carcinoma. Am. J. Clin. Oncol. 34(2), 150-154 (2010
27. Hainsworth JD, Sosman JA, Spigel DR et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. 23, 7889-7896 (2005 (Pubitemid 46657387)
28. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007 (Pubitemid 46089673)
29. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009
30. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 28, 1061-1068 (2010
31. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived rowth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 (2006 (Pubitemid 46630489)
32. Golshayan AR, George S, Heng DY et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J. Clin. Oncol. 27, 235-241 (2009
33. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon a, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007 (Pubitemid 46849157)
34. Dutcher JP de Souza P, McDermott D et al. Effect of temsirolimus versus interferon-a on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med. Oncol. 26, 202-209 (2009
35. Motzer RJ Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116, 4256-4265 (2010
36. Hainsworth JD, Spigel DR, Burris HA 3rd et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J. Clin. Oncol. 28, 2131-2136 (2010
37. Cangiano T, Liao J, Naitoh J et al. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J. Clin. Oncol. 17, 523-528 (1999 (Pubitemid 29075238)
38. Sella A, Logothetis CJ, Ro JY, Swanson DA, Samuels ML. Sarcomatoid renal cell carcinoma. A treatable entity. Cancer 60, 1313-1318 (1987 (Pubitemid 17152912)
39. Wood L, Amato R, Daliani D, Ayala A. Phase I study of outpatient interferon-a, doxorubicin, and ifosfamide for patients with metastatic sarcomatoid carcinoma. Presented at: ASCO Annual Meeting. Philadelphia, PA, USA, 15-18 May 1999 (Abstract 1371
40. Bangalore N, Bhargava P, Hawkins MJ. Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature. Ann. Oncol. 12, 271-274 (2001 (Pubitemid 32223881)
41. Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 101, 1545-1551 (2004 (Pubitemid 39318900)
42. Rashid MH, Welsh CT, Bissada NK, Chaudhary UB. Complete response to adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma. Am. J. Clin. Oncol. 28, 107-108 (2005 (Pubitemid 40209335)
43. Escudier B, Droz JP, Rolland F et al. Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a Phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J. Urol. 168, 959-961 (2002
44. Ishikawa T, Utoh M, Sawada N et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem. Pharmacol. 55, 1091-1097 (1998 (Pubitemid 28167730)
45. Pagliaro LC, Perez CA, Tu SM, Daliani DD. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma. Urol. Oncol. 24, 487-491 (2006 (Pubitemid 44810012)
46. Rini BI, Vogelzang NJ, Dumas MC et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J. Clin. Oncol. 18, 2419-2426 (2000). (Pubitemid 30415829)
47. Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain MJ. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J. Clin. Oncol. 20, 582-587 (2002 (Pubitemid 34072543)
48. Waters JS, Moss C, Pyle L et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br. J. Cancer 91, 1763-1768 (2004 (Pubitemid 39664962)
49. Stadler WM, Halabi S, Rini B et al. A Phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer 107, 1273-1279 (2006 (Pubitemid 44452776)
50. Tannir NM, Thall PF, Ng CS et al. A Phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J. Urol. 180, 867-872 (2008
51. Dutcher JP, Nanus D. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med. Oncol. DOI: 10.1007/ s12032-010-9649-2 (2010) (Epub ahead of print
52. Heng DY, Choueiri TK. Non-clear cell renal cancer: features and medical management. J. Natl Compr. Canc. Netw. 7, 659-665 (2009
53. Haas N, Manola J, Pins M et al. ECOG 8802: Phase II trial of doxorubicin and gemcitabine in metastatic renal cell carcinoma with sarcomatoid features. Presented at: 2009 Genitourinary Cancers Symposium. Orlando FL, USA, 26-28 February 2009 (Abstract 285
54. Pagliaro L, Tannir N, Thall P et al. Phase II study of bevacizumab, gemcitabine, and capecitabine treatment for metastatic or unresectable sarcomatoid renal cell carcinoma. Presented at: 2010 Genitourinary Cancers Symposium. San Francisco, CA, USA, 5-7 March 2010 (Abstract 375
55. Michaelson D, McDermott D, Atkins M et al. Phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Presented at: 2010 Genitourinary Cancers Symposium. San Francisco, CA, USA, 5-7 March 2010 (Abstract 340).